Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced it has entered into an exclusive license agreement with Lexicon Pharmaceuticals (Nasdaq: LXRX) for...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised AbbVie on the transaction, and Ropes & Gray advised Xilio Therapeutics. Xilio Therapeutics (Nasdaq: XLO) announced a strategic collaboration and option agreement...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Neomorph on the deal. Biotechnology company Neomorph announced a collaboration and option-to-license agreement with AbbVie (NYSE: ABBV) to develop novel molecular glue...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced expanding its collaboration with Valo Health, Inc. (Valo) in a deal worth up to...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised MOMA Therapeutics on the transaction. MOMA Therapeutics announced it has entered into a collaboration and exclusive license agreement with Bayer to develop...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced a multi-year partnership with NanoVation Therapeutics to develop genetic medicines for rare and cardiometabolic...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised CAMP4 Therapeutics on the transaction. CAMP4 Therapeutics Corporation, a clinical-stage biotechnology company, announced a research collaboration with BioMarin Pharmaceutical aimed at advancing...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Takeda Pharmaceuticals on the deal. Takeda Pharmaceuticals announced it has entered into a collaboration and exclusive license agreement with Degron Therapeutics (“Degron”)...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Gilgamesh Pharmaceuticals in a transaction. Gilgamesh Pharmaceuticals announced it has entered into a collaboration and option-to-license agreement with AbbVie (NYSE: ABBV) to...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Novavax Inc. in the transaction. Novavax Inc.(Nasdaq: NVAX) announced it has entered into a co-exclusive licensing agreement with French pharmaceutical company Sanofi...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised MOMA Therapeutics on the deal. MOMA Therapeutics announced a collaboration and licensing agreement with Swiss pharmaceutical leader Roche (SIX: RO, ROG; OTCQX: RHHBY)....
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Novo Nordisk on the deal. Novo Nordisk A/S and Valo Health, Inc. announced they have entered into an agreement to discover and...
You must be a Standard 1 Year member to access this content.
